Osteoporosis: Review of Treatment Modalities

Abdullah, Eman; Merkhan, Marwan M.; Althanoon, Zeina A.

doi:10.37648/ijrmst.v11i02.003

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the small sample size, it was noticed in this study that the association between BMI and age is unstable. Moreover, the limitation of the study could be due to variation in the response which is primarily linked to the surrounding milieu (52,53) which modulated cellular behaviour (54,55) based on localized tissue oxygen level (55,56) or or presence of sufficient vitamins and minerals (57,58).…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Activity of Platelet-Rich Plasma Treatment in the Inflammation Management Of knee Osteoarthritis: Experimental Study

Yousif¹,

Alzamily²,

Alsalman³

2023

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

Background:The level of pro-inflammatory Cluster of Differentiation 68 (CD 68) could be beneficial for examination as a biomarker for identifying cartilage or knee tissue degradation in joint problems. Because Cluster of Differentiation 68 appears to be linked to cell damage in the injury area, its measurement may be an effective and sensitive tool for detecting the early development of knee osteoarthritis (KOA) in people at risk for knee osteoarthritis. Aim of the study:The study aimed to evaluate which type of PRP (Pure-PRP and leukocyte-PRP) are suitable for patients with KOA via assessing the levels of serum CD 68 concentration. Materials and Methods: Serum Cluster of Differentiation 68 level was computed using ELISA kits. The experimental study comprises 21 pure-platelet-rich plasma (P-PRP) injections,11 leukocytes plateletrich plasma (L-PRP) injections, and 16 control groups. Ranged from 35-75 years old. All patients with diabetes mellitus, autoimmune disease, and severe knee osteoarthritis were excluded from this study. The period of the study was between November 2021 to June 2022. This study assessed other factors such as age, sex, family inheritance, and body mass index (BMI). The level of CD 68 was measured in the serum before and after the injection for six weeks. Results:The level of the study showed CD 68 elevated before injection in patients with knee osteoarthritis. A significant decrease of CD 68 (P< 0.01-P<0.001) in the serum concentration after injection as compared to before injection. However, the concentration was significantly higher than the control. Conclusions: In conclusion, both P-PRP and L-PRP demonstrated anti-inflammatory properties. Patients in both groups experienced a significant decrease in CD 68 serum levels, however, the P-PRP was more effective than the L-PRP.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Activity of Platelet-Rich Plasma Treatment in the Inflammation Management Of knee Osteoarthritis: Experimental Study

Yousif¹,

Alzamily²,

Alsalman³

2023

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

show abstract

“…Another study found that lisinopril increased the expression of CD34 in bone tissue in a mouse model of osteoporosis. 6 While the exact mechanism by which lisinopril increases CD34 expression in bone tissue is not fully understood, it is thought to be related to the drug's ability to inhibit the ACE enzyme. Inhibition of ACE can lead to an increase in the production of a hormone called angiotensin II, which has been shown to stimulate the production of CD34 in bone tissue.…”

Section: Introductionmentioning

confidence: 99%

Lisinopril-Induced CD34 Bone Healing Marker

Alsaffar¹,

Al-Saffar²,

Mahmood³

2023

Pharmacogn J.

View full text Add to dashboard Cite

Background: Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that is commonly used to treat high blood pressure and heart failure. While it is generally well-tolerated, some studies have suggested that it may affect bone healing, suggesting that lisinopril treatment was associated with an increase in the CD34 bone healing marker in patients with tibial fractures. CD34 is a protein that is involved in the formation of new blood vessels and has been shown to play a role in bone healing. Methods: The study used 24 rabbits with artificially induced tibial bone fracture divided into 4 groups (6 rabbits each), the control group treated with distilled water and 3 groups treated with lisinopril. Each group were sacrificed for immunohistochemical study on 3 timepoints at day 7, 14, and 21. Results: Indicated that the lisinopril group had significantly higher levels of CD34 than the control group. Conclusion: While the results of this study suggest that lisinopril may have a positive effect on bone healing, more research is needed to confirm these findings and to determine the mechanisms by which lisinopril may affect bone healing. It is also important to note that lisinopril may have other potential side effects, and patients should discuss any concerns with their healthcare provider.

show abstract

The Relationship of Osteoporosis with Menopause: Review of Article

Alsarraje¹,

Alhyali²

2022

IJRMST

View full text Add to dashboard Cite

Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only antiosteoporosis medication that has been shown to be effective regardless of baseline risk . There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.

show abstract

Osteoporosis: Review of Treatment Modalities

Cited by 3 publications

References 22 publications

Anti-Inflammatory Activity of Platelet-Rich Plasma Treatment in the Inflammation Management Of knee Osteoarthritis: Experimental Study

Anti-Inflammatory Activity of Platelet-Rich Plasma Treatment in the Inflammation Management Of knee Osteoarthritis: Experimental Study

Lisinopril-Induced CD34 Bone Healing Marker

The Relationship of Osteoporosis with Menopause: Review of Article

Contact Info

Product

Resources

About